SHANGHAI – Shanghai-based biotech Zai Labs Ltd. is adding biologics manufacturing capabilities to its business model of developing new drugs for China via in-licensing assets and in-house biologics discovery. The site will be located in Suzhou Biobay and will make clinical trial quantity Biotherapeutics, with the possibility of scaling to commercial quantities at a later stage.